Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Zoetis (ZTS) is under pressure after first quarter 2026 earnings missed analyst forecasts and management cut full year revenue and earnings guidance, highlighting softer U.S. companion animal demand and tougher competition in dermatology and pain.
See our latest analysis for Zoetis.
That weaker U.S. companion animal backdrop is showing up clearly in the share price, with Zoetis stock down about 38.5% on a 1 month share price basis and the 1 year total shareholder return declining roughly 53.8%. This suggests momentum has faded as investors reassess risk and growth expectations.
If this kind of volatility has you looking around the sector, it could be a moment to compare Zoetis with other healthcare and animal health plays using our screener for 32 healthcare AI stocks
With Zoetis now trading around $74.22, at what looks like a steep discount to analyst targets and some intrinsic value estimates, the key question is whether this reset creates a genuine buying window or if the market is correctly pricing slower future growth.
Most Popular Narrative: 50.8% Undervalued
The most followed Zoetis narrative pegs fair value at $151.00, almost double the last close of $74.22. This sets up a very different picture compared with recent price action.
The analysts have a consensus price target of $190.285 for Zoetis based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $230.0, and the most bearish reporting a price target of just $153.0.
Curious how a fair value near double the current share price is built? Revenue, earnings and margins all play a part, together with a higher future P/E and a specific discount rate that tie the whole narrative together.
Result: Fair Value of $151.00 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, there are clear pressure points, including competitive threats in key franchises and concerns around the osteoarthritis pain portfolio that could undermine the bullish fair value case.
Find out about the key risks to this Zoetis narrative.
Next Steps
The mix of concern and optimism around Zoetis is clear. It may be useful to review the data yourself and decide quickly where you stand based on the 5 key rewards and 1 important warning sign
Looking for more investment ideas?
If you leave it here, you could miss stocks that better match your goals. Use the screeners below to quickly surface focused, data driven ideas.